Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec

Executive Summary

As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.

You may also be interested in...



New Opportunity For CER As Placebo Trials Show Shrinking Drug Efficacy Margins – Health Affairs

Authors of a Health Affairs article find the effect of active drugs versus placebo has declined in controlled trials over time, suggesting to them that more attention should be focused on understanding the clinical value of existing treatments, including establishing equivalence of efficacy and focusing on differences in safety, cost and tolerability.

Develop CER Strategies, Or Be Left Behind, GSK Exec Says

Execs from GlaxoSmithKline and OptumInsight offer insight on the need for pharma companies to develop strategies that account for the growing role comparative effectiveness research is playing in reforming health care, a role that will continue despite what happens in legal and legislative circles in Washington, D.C.

PCORI Receives More Than 850 Applications For 40 Pilot Project Grants

Grants will help inform Methodology Committee activities; member Clyde Yancy sees committee’s work as setting the bar for how to conduct patient-centered outcomes research.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel